Subgroup survival analysis of patients with MG stratified by IGHV mutation status. (A) The proportion of patients with MG in each risk group of CLL-IPI. (B-C) PFS and OS in patients with CLL with mutated IGHV. (D-E) PFS and OS in patients with CLL with unmutated IGHV.